As shown in Fig. 4a, SHR1032 suppressed THP1-STING-R232 cell growth (GI50 = 23 nM) even more effectively than cytarabine (GI50 = 100 nM), which is the drug used as standard of care for AML. Here, STING1 is linked to acute myeloid leukemia.